H5N1 News and Research

Latest H5N1 News and Research

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

CEL-SCI Corporation announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine in Israel.

31 Mar 2011

First evidence of H5N1 transmission between domestic farms and wild birds

Wild migratory birds may indeed play a role in the spread of bird flu, also known as highly pathogenic avian influenza H5N1.

25 Mar 2011

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

NanoViricides, Inc. reported dramatically improved antiviral efficacy with its optimized FluCide™ drug candidates in its most recent animal study.

21 Mar 2011

EU parliament approves resolution calling for countries to revise pandemic response

On the heels of the release of a draft report by an independent panel of experts examining the WHO's response to H1N1, BMJ News reports on a recently approved resolution and accompanying report released by the European Union parliament that calls on EU countries to revise their flu prevention plans "to make them more effective, coherent, and flexible" and for the WHO to revise its definition of pandemic to take into account not only geographical spread of disease but also severity.

16 Mar 2011

NIH awards InDevR $3 million Phase II SBIR grant for influenza-related research

InDevR announced today that it has been awarded a Phase II Small Business Innovation Research grant from the National Institutes of Health in the amount of $3 million over the next 3 years.

11 Mar 2011

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult population for its proprietary inactivated vaccine against human enterovirus 71, which causes hand, foot, and mouth disease.

10 Mar 2011

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV) to China's State Food and Drug Administration (SFDA) on March 3, 2011.

3 Mar 2011

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

NanoViricides, Inc.announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company's anti-viral technology and more specifically, results from both in-vitro and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever.

23 Feb 2011

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Vical Incorporated announced today that the company has extended its relationship with the U.S. Naval Medical Research Center to develop its platform technology for the rapid development and production of vaccines against emerging infectious diseases.

22 Feb 2011

Nasal spray vs. injection -- what would you prefer?

Adelaide researchers have taken a step closer to the development of a universal flu vaccine, with results of a recent study showing that a vaccine delivered by a simple nasal spray could provide protection against influenza.

19 Feb 2011

Daily Report Global Health Conversations: Global health funding and the FY11, FY12 budgets

As Congress considers both the FY11 and FY12 budgets, the Kaiser Daily Global Health Policy Report's Jaclyn Schiff spoke to Adam Wexler, a senior policy analyst for global health policy at the Kaiser Family Foundation, about the potential implications for global health funding.

18 Feb 2011

Rising number of livestock diseases threatens public health, food security in developing countries, report says

"A growing number of livestock, such as cows and pigs, are fuelling new animal epidemics worldwide and posing more severe problems in developing countries as it threatens their food security, according to a report [.pdf] released on Friday" during an international conference in New Delhi, India, on Leveraging Agriculture for Improving Nutrition & Health, Reuters reports (Lyn, 2/11).

14 Feb 2011

Avian flu vaccine stockpiled in 2004 still useful

A stockpiled vaccine designed to fight a strain of avian flu that circulated in 2004 can be combined with a vaccine that matches the current strain of bird flu to protect against a potential pandemic, researchers from Saint Louis University's Center for Vaccine Development have found.

10 Feb 2011

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received Food and Drug Administration ("FDA") clearance for its phase I H1N1 influenza VLP vaccine candidate ("H1N1 vaccine") clinical trial in the United States.

9 Feb 2011

Total flu cover with one shot

In a medical breakthrough, English scientists have developed a so-called “universal” vaccine to influenza - one that protects against all strains of the potentially deadly illness. This would do away with the need for a new vaccine each flu season they say. Seasonal flu affects up to 20 percent of the population and kills an average of 24,600 people each year. This vaccine would act against swine flu as well assure researchers.

8 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Inovio Pharmaceuticals, Inc., a leader in the development of novel therapeutic and preventive vaccines against cancers and infectious diseases, announced today the presentation of recent preclinical data using its next generation of minimally invasive intradermal (skin) electroporation delivery devices at the Phacilitate Vaccine Forum 2011 in Washington, DC.

28 Jan 2011

Lancet series examines health issues facing populations in Southeast Asia

"Southeast Asia's 600 million people are facing a raft of new health challenges as the disaster-prone region undergoes some of the world's fastest social change," according to a series of papers and commentary pieces, published Tuesday in the Lancet, Agence France-Presse reports (O'Brien, 1/25).

27 Jan 2011

Bird flu outbreak in Japan

After six birds were confirmed to have avian flu, the Miyazaki Prefectural Government has begun culling more than 10,000 chickens at a local poultry farm southwest Japan.

23 Jan 2011

H5N1 News and Research

Latest H5N1 News and Research

CEL-SCI to initiate Multikine Phase III trial against head and neck cancer in Israel

First evidence of H5N1 transmission between domestic farms and wild birds

NanoViricides reports improved efficacy with optimized FluCide nanoviricide drug candidates for influenza

EU parliament approves resolution calling for countries to revise pandemic response

NIH awards InDevR $3 million Phase II SBIR grant for influenza-related research

Positive preliminary results from Sinovac EV71 vaccine phase I trial in adults

Sinovac submits clinical trial application for 13-valent pneumococcal conjugate vaccine to China SFDA

Study results of NanoViricides anti-dengue drug candidates presented at NIH/NIAID sponsored conference

Vical extends relationship with U.S. NMRC for emerging disease vaccine platform

Nasal spray vs. injection -- what would you prefer?

Daily Report Global Health Conversations: Global health funding and the FY11, FY12 budgets

Rising number of livestock diseases threatens public health, food security in developing countries, report says

Avian flu vaccine stockpiled in 2004 still useful

Medicago granted FDA clearance for clinical development of seasonal flu vaccine

Total flu cover with one shot

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Preclinical data on Inovio’s intradermal electroporation delivery devices presented at Phacilitate Vaccine Forum

Lancet series examines health issues facing populations in Southeast Asia

Bird flu outbreak in Japan

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in